Current Monitoring in a Microchannel with Repeated Constrictions for Accurate Detection of Sample Location in Isotachophoresis by Merav Karsenty (1694221)

“…We demonstrate the use of the technique to deliver sample to a designated location in the channel with an accuracy as low as 50 μm. …”

Current Monitoring in a Microchannel with Repeated Constrictions for Accurate Detection of Sample Location in Isotachophoresis by Merav Karsenty (1694221)

“…We demonstrate the use of the technique to deliver sample to a designated location in the channel with an accuracy as low as 50 μm. …”

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

Inverse Phase Transition in Droplet Clusters Levitating over the Locally Heated Water Layer by Alexander A. Fedorets (7376702)

“…Self-assembled microdroplet clusters can levitate above a locally heated water surface. Normally, the temperature of droplets is in the range of 50–95 °C. …”

Anthelmintics Derived from the Kinase Inhibitor SGI-1776 for the Treatment of Gastrointestinal Worm Infections by Mostafa A. Elfawal (22430138)

“…We demonstrate the efficacy of optimized compound <b>50</b> as a new oral anthelmintic, which demonstrated better gut restriction properties and significantly reduced the fecundity of T. muris whipworm adults in infected mice. …”

Habitual Functional Electrical Stimulation Therapy Improves Gait Kinematics and Walking Performance, but Not Patient-Reported Functional Outcomes, of People with Multiple Sclerosis... by Marietta L. van der Linden (617342)

“…Five participants exceeded the Minimally Detectable Change (MDC) for a training effect on the 10mWT, but only two did so for the 2 minWT. No effects of the use of FES for 12 weeks were found for MSWS, MSIS29, FSS or step count.…”

Increased Locomotory Healthspan and Survival with <i>pck-2</i> Overexpression, as Well as Expression of <i>pck-2</i> in the Intestine, Require <i>daf-16</i>. by Brian Onken (86790)

Mean scores of IB-DE, IH-DE, and IB-DE items in Sample 1 and Sample 2 as well as women and men across the samples. by Aistė Ambrasė (22505574)

Fig 4 - by Hyuk Sung Yoon (20208672)

DataSheet5_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet6_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet4_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

Data_Sheet_1_Propofol EC50 for inducing loss of consciousness in patients under combined epidural-general anesthesia or general anesthesia alone: a randomized double-blind study.do... by Jiangling Wang (11929476)

“…</p>Conclusion<p>Concomitant epidural anesthesia reduced by 15% the EC₅₀ of predicted Ce_prop for LOC, decreased the consumptions of propofol and remifentanil during maintenance of anesthesia, and fastened recovery from anesthesia.…”

Baseline characteristics. by Daniela Sánchez-Santiesteban (21192342)

“…The RII indicated a 50% higher risk of death in the lowest income group (RII: 1.50; 95% CI: 1.13–1.99), while the SII revealed an absolute difference of 0.16 deaths per 1,000 individuals (p=0.01).…”

Fig 4 - by Leena Inkilä (20614460)

Composite age-depth model and sediment accumulation rate for BF19 & BF87. by John A. F. Wendt (19976392)